Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2256-2264.e3

  Almers, Lucy M ^a   Graham, James E ^b   Havel, Peter J ^b   Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipokines; Adiponectin; Barrett's Esophagus; BMI; Esophageal Adenocarcinoma

Indexed keywords

ADIPONECTIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG USE; EDUCATIONAL STATUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RACE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SMOKING HABIT; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; CALIFORNIA; COMPLICATION; MIDDLE AGED; YOUNG ADULT;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; BARRETT ESOPHAGUS; CALIFORNIA; CASE-CONTROL STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

EID: 84947488112     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.01.009     Document Type: Article

References (47)

1. Blot W.J., McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Oncol 1999, 26:2-8.
2. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
3. Reynolds R.P. Pathophysiology and investigation of Barrett's esophagus. Can J Gastroenterol 1997, 11(Suppl B):41B-44B.
4. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244. quiz e32.
5. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007, 133:34-41. quiz 311.
6. Murray L., Romero Y. Role of obesity in Barrett's esophagus and cancer. Surg Oncol Clin N Am 2009, 18:439-452.
7. Samanic C., Gridley G., Chow W.H., et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004, 15:35-43.
8. Sharma P., Falk G.W., Weston A.P., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006, 4:566-572.
9. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004, 53(Suppl 1):S143-S151.
10. Swarbrick M.M., Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Dis 2008, 6:87-102.
11. Ajuwon K.M., Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1220-R1225.
12. Chen H., Montagnani M., Funahashi T., et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
13. Corley D.A. Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link?. Gut 2007, 56:1493-1494.
14. Yamamoto S., Watabe K., Araki H., et al. Protective role of adiponectin against ethanol-induced gastric injury in mice. Am J Physiol Gastrointest Liver Physiol 2012, 302:G773-G780.
15. Kupchak B.R., Garitaonandia I., Villa N.Y., et al. Antagonism of human adiponectin receptors and their membrane progesterone receptor paralogs by TNFalpha and a ceramidase inhibitor. Biochemistry 2009, 48:5504-5506.
16. Miele M., Costantini S., Colonna G. Structural and functional similarities between osmotin from nicotiana tabacum seeds and human adiponectin. PLoS One 2011, 6:e16690.
17. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992, 82:703-710.
18. Sharma P., McQuaid K., Dent J., et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310-330.
19. Rothman K.J. Modern epidemiology 1998, Lippincott-Raven, Philadelphia.
20. Choi K.M., Lee J., Lee K.W., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 2004, 61:75-80.
21. Pischon T., Hotamisligil G.S., Rimm E.B. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003, 49:650-652.
22. Block G., Thompson F.E., Hartman A.M., et al. Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period. J Am Diet Assoc 1992, 92:686-693.
23. Locke G.R., Talley N.J., Weaver A.L., et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994, 69:539-547.
24. Breslow N.E. Statistical methods in cancer research. Volume 1: the analysis of case-control studies 1980, International Agency for Research on Cancer, Lyon, France.
25. Ferris B.G. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978, 118:1-120.
26. Zhao Y., Ash A.S., Ellis R.P., et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care 2005, 43:34-43.
27. Zhao Y., Ellis R.P., Ash A.S., et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res 2001, 36:180-193.
28. Hosmer D.W. Applied logistic regression 2000, Wiley, New York.
29. Isobe T., Saitoh S., Takagi S., et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005, 153:91-98.
30. Kern P.A., Di Gregorio G.B., Lu T., et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52:1779-1785.
31. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
32. Takefuji S., Yatsuya H., Tamakoshi K., et al. Smoking status and adiponectin in healthy Japanese men and women. Prev Med 2007, 45:471-475.
33. Cook M.B., Shaheen N.J., Anderson L.A., et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012, 142:744-753.
34. Goktas S., Yilmaz M.I., Caglar K., et al. Prostate cancer and adiponectin. Urology 2005, 65:1168-1172.
35. Ishikawa M., Kitayama J., Kazama S., et al. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005, 11:466-472.
36. Mantzoros C., Petridou E., Dessypris N., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89:1102-1107.
37. Petridou E., Mantzoros C., Dessypris N., et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003, 88:993-997.
38. Wei E.K., Giovannucci E., Fuchs C.S., et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-1694.
39. Ogunwobi O.O., Beales I.L. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008, 285:43-50.
40. Yildirim A., Bilici M., Cayir K., et al. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009, 39:92-96.
41. Howard J.M., Beddy P., Ennis D., et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010, 97:1020-1027.
42. Rubenstein J.H., Kao J.Y., Madanick R.D., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
43. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
44. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238 e3.
45. Kramer J.R., Fischbach L.A., Richardson P., et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol 2013, 11:373-381 e1.
46. Kubo A., Cook M.B., Shaheen N.J., et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013, 62:1684-1691.
47. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.